Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P23786: Variant p.Pro227Leu

Carnitine O-palmitoyltransferase 2, mitochondrial
Gene: CPT2
Feedback?
Variant information Variant position: help 227 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Proline (P) to Leucine (L) at position 227 (P227L, p.Pro227Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CPT2D. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 227 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 658 The length of the canonical sequence.
Location on the sequence: help VNAYPLDMSQYFRLFNSTRL P KPSRDELFTDDKARHLLVLR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         VNAYPLDMSQYFRLFNSTRLPKPSRDELFTDDKARHLLVLR

Mouse                         VNAYPLDMSQYFRLFNSTRIPKPSRDELFTDTKARHLLVLR

Rat                           VNAYPLDMSQYFRLFNSTRIPRPNRDELFTDTKARHLLVLR

Bovine                        VNAYPLDMSQYYRLFNSTRLPRPHRDELFTDDKARHLLVLR

Xenopus laevis                VNAYPLDMSQYFRLFNCTRIPKPNRDELLTDEKGRHLLVLR

Xenopus tropicalis            VNAYPLDMSQYFRLFNGTRIPKPNRDELWTDEKGRHLLVLR

Zebrafish                     VNAYPLDMSQYFRLFNSTRIPKYKRDELLTDDRGRHLLVMK
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 26 – 658 Carnitine O-palmitoyltransferase 2, mitochondrial
Topological domain 209 – 658 Mitochondrial matrix
Modified residue 239 – 239 N6-acetyllysine; alternate
Modified residue 239 – 239 N6-succinyllysine; alternate



Literature citations
Lethal carnitine palmitoyltransferase (CPT) II deficiency in newborns: a molecular-genetic study.
Taroni F.; Gellera C.; Cavadini P.; Baratta S.; Lamantea E.; Dethlefs S.; Didonato S.; Reik R.A.; Benke P.J.;
Cited for: VARIANT CPT2D LEU-227; Identification of four novel mutations in patients with carnitine palmitoyltransferase II (CPT II) deficiency.
Yang B.-Z.; Ding J.-H.; Dewese T.; Roe D.; He G.; Wilkinson J.; Day D.W.; Demaugre F.; Rabier D.; Brivet M.; Roe C.;
Mol. Genet. Metab. 64:229-236(1998)
Cited for: VARIANTS CPT2D LEU-113; GLN-151; LEU-227; ARG-550 AND SER-604; VARIANTS ILE-368 AND VAL-647;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.